Duopharma Biotech to sustain earnings growth, analysts say after strong 2024Duopharma Biotech Bhd (KL:DPHARMA) may sustain its earnings growth, thanks to lower input costs and higher government pharmaceutical spending, analysts said following a 19% net profit growth in 2024.